Details of the Drug Reposition

General Information of This Drug (ID: DML44FR)

• Drug Name: AR-42 (DML44FR)
• Synonyms: AR-42; 935881-37-1; OSU-HDAC42; AR 42; (S)-HDAC-42; (S)-N-Hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide; UNII-E0GG29V0AQ; (S)-HDAC 42; E0GG29V0AQ; AR42; HDAC-42; AR-42 (HDAC-42); N-hydroxy-4-{[(2S)-3-methyl-2-phenylbutanoyl]amino}benzamide; N-hydroxy-4-[[(2S)-3-methyl-2-phenylbutanoyl]amino]benzamide; AR-42 (OSU-HDAC42); AC1OCFYN; cc-20; OSU-HDAC 42; MLS006011089; CHEMBL191482; SCHEMBL2348844; OSU-42; DTXSID4042678; NOCAS_42678; CTK8C1969; AOB3995; N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide; MolPort-009-019-571
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

2 Phase 1/2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Chronic lymphocytic leukaemia	DISEXWC3	2A82.0	Phase 1/2	[1]
Multiple myeloma	DISEWP9B	2A83	Phase 1/2	[1]

References

• [1] Clinical pipeline report, company report or official report of Arno Therapeutics.